IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
13 1월 2024 - 6:05AM
IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”),
developer of the ProSense® System, a minimally-invasive
cryoablation technology that destroys tumors by freezing as an
alternative to surgical tumor removal, today announced that it
has received a written notice from The Nasdaq Stock Market LLC
("Nasdaq") that the Company has regained compliance with the
minimum bid price requirement for continued listing set forth in
Nasdaq Listing Rule 5550(a)(2), which requires listed securities,
including the Company's ordinary shares, to maintain a minimum bid
price of $1.00 per share.
The Nasdaq staff made this determination of
compliance after the closing bid price of the Company's ordinary
shares was at $1.00 per share or greater for the 10 consecutive
business days prior to the date of the notice. Accordingly, the
Company has regained compliance with Nasdaq Listing Rule
5550(a)(2), and Nasdaq considers the prior bid price deficiency
matter now closed.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and
markets ProSense®, an advanced liquid-nitrogen-based cryoablation
therapy for the treatment of tumors (benign and cancerous) by
freezing, with the primary focus areas being breast, kidney, bone
and lung cancer. Its minimally invasive technology is a safe and
effective alternative to hospital surgical tumor removal that is
easily performed in a relatively short procedure. The system is
marketed and sold worldwide for the indications cleared and
approved to date including in the U.S., Europe, and China.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statement in this press release when it discusses the
continued listing or meeting of the continued listing
requirements. Forward-looking statements are not historical
facts, and are based upon management’s current expectations,
beliefs and projections, many of which, by their nature, are
inherently uncertain. Such expectations, beliefs and projections
are expressed in good faith. However, there can be no assurance
that management’s expectations, beliefs and projections will be
achieved, and actual results may differ materially from what is
expressed in or indicated by the forward-looking
statements. Important factors that could cause actual results,
developments and business decisions to differ materially from those
anticipated in these forward-looking statements include, among
others: the Company’s planned level of revenues and capital
expenditures; the Company’s available cash and its ability to
obtain additional funding; the Company’s ability to market and sell
its products; legal and regulatory developments in the United
States and other countries; the Company’s ability to maintain
its relationships with suppliers, distributors and other partners;
the Company’s ability to maintain or protect the validity of its
patents and other intellectual property; the Company’s ability to
expose and educate medical professionals about its products;
political, economic and military instability in the Middle
East, specifically in Israel; as well as those factors set
forth in the Risk Factors section of the Company’s Annual Report on
Form 20-F for the year ended December 31, 2022 filed with the SEC
on March 29, 2023, and other documents filed with or furnished to
the SEC which are available on the SEC’s website, www.sec.gov. The
Company undertakes no obligation to update these statements for
revisions or changes after the date of this release, except as
required by law.
IR Contact:
Email: investors@icecure-medical.comMichael
PolyviouPhone: 732-232-6914Todd KehrliPhone: 310-625-4462
IceCure Medical (NASDAQ:ICCM)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
IceCure Medical (NASDAQ:ICCM)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024